Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Real-Time Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01093 CSPC PHARMA
RTNominal down17.660 -0.580 (-3.180%)
Research Report

16/01/2020 10:50

{I-bank focus}Morgan trims CSPC Pharma (01093) to HK$23.2

[ET Net News Agency, 16 January 2020] Morgan Stanley trimmed its target price for CSPC
Pharmaceutical Group (01093) to HK$23.2 from HK$25 and maintained its "overweight" rating.
The research house kept itsd 2019 forecasts largely unchanged. It cut 2020-21 sales
estimates by 4% each, mainly reflecting lower sales forecasts for Keaili (albumin-bound
paclitaxel). The national bidding for centralized procurement will open on 17 January
2020. CSPC will compete with three other companies for 3 spots in this category.
In addition, the national procurement amount was only 136.9 thousand vials, well below
CSPC's 2019 sales volume (assuming Rmn1.5bn sales in 2019 and ASP of Rmb2500, CSPC would
be selling 600 thousand vials in 2019).
Given the pricing pressure and uncertainties on volume, Morgan cut its sales growth
assumption for Keaili in 2020/2021 from 70%/20% to 20%/15%, respectively. This translates
into Rmb2.05bn sales in 2020 and Rmb2.36bn sales in 2021. As a result, Morgan's EPS
forecasts for 2020 and 2021 were lowered less by 1% and 3%. (KL)

Remark: Real time quote last updated: 28/02/2020 10:55
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2020 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.